These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24700697)

  • 1. Hepatitis C virus serine protease: synthesis of radioactive and stable isotope-labeled potent inhibitors.
    Latli B; Hrapchak M; Gorys V; Llinàs-Brunet M; Campbell SS; Song J; Senanayake CH
    J Labelled Comp Radiopharm; 2014 May; 57(5):350-7. PubMed ID: 24700697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of two potent glucocorticoid receptor agonists labeled with carbon-14 and stable isotopes.
    Latli B; Reeves JT; Tan Z; Hrapchak M; Song JJ; Busacca CB; Senanayake CH
    J Labelled Comp Radiopharm; 2015; 58(11-12):445-52. PubMed ID: 26391408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS
    Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent inhibitors of HCV-NS3 protease derived from boronic acids.
    Venkatraman S; Wu W; Prongay A; Girijavallabhan V; George Njoroge F
    Bioorg Med Chem Lett; 2009 Jan; 19(1):180-3. PubMed ID: 19022670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
    Llinàs-Brunet M; Bailey MD; Bolger G; Brochu C; Faucher AM; Ferland JM; Garneau M; Ghiro E; Gorys V; Grand-Maître C; Halmos T; Lapeyre-Paquette N; Liard F; Poirier M; Rhéaume M; Tsantrizos YS; Lamarre D
    J Med Chem; 2004 Mar; 47(7):1605-8. PubMed ID: 15027850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease.
    Chen KX; Njoroge FG; Prongay A; Pichardo J; Madison V; Girijavallabhan V
    Bioorg Med Chem Lett; 2005 Oct; 15(20):4475-8. PubMed ID: 16112859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of (1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid vinyl-ACCA) derivatives: key intermediates for the preparation of inhibitors of the hepatitis C virus NS3 protease.
    Beaulieu PL; Gillard J; Bailey MD; Boucher C; Duceppe JS; Simoneau B; Wang XJ; Zhang L; Grozinger K; Houpis I; Farina V; Heimroth H; Krueger T; Schnaubelt J
    J Org Chem; 2005 Jul; 70(15):5869-79. PubMed ID: 16018680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A protease.
    Andrews DM; Carey SJ; Chaignot H; Coomber BA; Gray NM; Hind SL; Jones PS; Mills G; Robinson JE; Slater MJ
    Org Lett; 2002 Dec; 4(25):4475-8. PubMed ID: 12465916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel five-lipoxygenase activity protein inhibitor labeled with carbon-14 and deuterium.
    Latli B; Hrapchak M; Gao JJ; Busacca CA; Senanayake CH
    J Labelled Comp Radiopharm; 2015 Jul; 58(9):390-4. PubMed ID: 26190342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent inhibitors of the hepatitis C virus NS3 protease: design and synthesis of macrocyclic substrate-based beta-strand mimics.
    Goudreau N; Brochu C; Cameron DR; Duceppe JS; Faucher AM; Ferland JM; Grand-Maître C; Poirier M; Simoneau B; Tsantrizos YS
    J Org Chem; 2004 Sep; 69(19):6185-201. PubMed ID: 15357576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
    Ding CZ; Zhang YK; Li X; Liu Y; Zhang S; Zhou Y; Plattner JJ; Baker SJ; Liu L; Duan M; Jarvest RL; Ji J; Kazmierski WM; Tallant MD; Wright LL; Smith GK; Crosby RM; Wang AA; Ni ZJ; Zou W; Wright J
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7317-22. PubMed ID: 21067923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG; Chen KX; Shih NY; Piwinski JJ
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment and application of high throughput screening model for hepatitis C virus NS3-4A protease inhibitors in vitro.
    Jian-rui L; Yan-bin W; Shu-yi S; Hong-shan C; Jian-dong J; Zong-gen B
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Feb; 33(1):98-101. PubMed ID: 21375947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.
    Reiser M; Hinrichsen H; Benhamou Y; Reesink HW; Wedemeyer H; Avendano C; Riba N; Yong CL; Nehmiz G; Steinmann GG
    Hepatology; 2005 Apr; 41(4):832-5. PubMed ID: 15732092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
    Duan M; Kazmierski W; Crosby R; Gartland M; Ji J; Tallant M; Wang A; Hamatake R; Wright L; Wu M; Zhang YK; Ding CZ; Li X; Liu Y; Zhang S; Zhou Y; Plattner JJ; Baker SJ
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2993-6. PubMed ID: 22425454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of novel potent hepatitis C virus NS3 protease inhibitors: discovery of 4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid as a N-acyl-L-hydroxyproline bioisostere.
    Thorstensson F; Wångsell F; Kvarnström I; Vrang L; Hamelink E; Jansson K; Hallberg A; Rosenquist S; Samuelsson B
    Bioorg Med Chem; 2007 Jan; 15(2):827-38. PubMed ID: 17107807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel P2 substituted 4-biaryl proline inhibitors of hepatitis C virus NS3 serine protease.
    Bailey MD; Halmos T; Lemke CT
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4436-40. PubMed ID: 23773864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
    Thomson JA; Perni RB
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease.
    Chen KX; Njoroge FG; Pichardo J; Prongay A; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2005 Oct; 48(20):6229-35. PubMed ID: 16190750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
    Li X; Zhang YK; Liu Y; Zhang S; Ding CZ; Zhou Y; Plattner JJ; Baker SJ; Liu L; Bu W; Kazmierski WM; Wright LL; Smith GK; Jarvest RL; Duan M; Ji JJ; Cooper JP; Tallant MD; Crosby RM; Creech K; Ni ZJ; Zou W; Wright J
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7493-7. PubMed ID: 21041080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.